X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/01/11/2807778/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-in-Japan-for-Idiopathic-Pulmonary-Fibrosis.html
https://www.globenewswire.com/news-release/2023/06/06/2682659/0/en/Algernon-Pharmaceuticals-to-Present-Phase-2-Ifenprodil-Cough-Data-at-the-2023-American-Cough-Conference.html
https://www.globenewswire.com/news-release/2023/01/09/2585006/0/en/Algernon-Pharmaceuticals-Announces-Plans-for-a-180-Patient-Phase-2b-Chronic-Cough-Study-of-Ifenprodil.html
https://www.globenewswire.com//news-release/2022/12/05/2567239/0/en/Algernon-Pharmaceuticals-Receives-U-S-FDA-Orphan-Drug-Designation-for-Ifenprodil-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html
https://endpts.com/fda-grants-orphan-drug-designation-to-algernons-ifenprodil-while-exclusivity-remains-unclear/
https://www.globenewswire.com/news-release/2022/09/19/2518160/0/en/Algernon-Pharmaceuticals-Files-for-Orphan-Designation-with-the-U-S-FDA-for-Ifenprodil-as-a-Treatment-of-IPF.html
https://www.globenewswire.com/news-release/2022/09/01/2508382/0/en/Algernon-Pharmaceuticals-Reports-Positive-Results-from-Full-Data-Set-of-its-Phase-2-Study-of-Ifenprodil-for-IPF-and-Chronic-Cough.html
https://www.globenewswire.com/news-release/2022/07/28/2487666/0/en/Algernon-Pharmaceuticals-Reports-Additional-Positive-Data-From-its-Phase-2-Study-of-Ifenprodil-for-IPF-and-Chronic-Cough.html
https://www.globenewswire.com/news-release/2022/07/18/2481017/0/en/Algernon-Pharmaceuticals-Hits-Co-Primary-Endpoint-in-its-Phase-2-Study-of-Ifenprodil-for-Idiopathic-Pulmonary-Fibrosis-and-Chronic-Cough.html
https://www.globenewswire.com/news-release/2022/06/22/2466960/0/en/Algernon-Pharmaceuticals-Announces-Issuance-of-Patent-for-Ifenprodil-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html
https://www.globenewswire.com/news-release/2022/06/21/2465937/0/en/Algernon-Announces-Patients-Requested-Ongoing-Supply-of-Ifenprodil-after-IPF-and-Chronic-Cough-Phase-2-Study-Ended.html
https://www.globenewswire.com/news-release/2022/02/04/2379200/0/en/Algernon-Pharmaceuticals-Announces-Completion-of-Enrollment-in-its-Phase-2-Study-of-Ifenprodil-for-IPF-and-Chronic-Cough.html
https://www.globenewswire.com/news-release/2022/01/28/2374942/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-Application-for-Idiopathic-Pulmonary-Fibrosis.html
https://www.clinicaltrialsarena.com/news/fda-algernon-cough-trial/
https://www.globenewswire.com/news-release/2021/11/24/2340463/0/en/Algernon-Pharmaceuticals-Announces-Positive-Feedback-from-U-S-FDA-for-Phase-1-Ifenprodil-Small-Cell-Lung-Cancer-Study.html
https://www.globenewswire.com/news-release/2021/10/08/2311085/0/en/Algernon-Pharmaceuticals-Files-U-S-FDA-Pre-IND-Meeting-Request-for-Ifenprodil-Chronic-Cough-Phase-2-Study.html
https://www.globenewswire.com/news-release/2021/05/12/2228023/0/en/Algernon-Pharmaceuticals-Announces-Ifenprodil-Reduced-Interleukin-6-in-Phase-2b-3-COVID-Study.html
https://www.globenewswire.com/news-release/2021/04/08/2206560/0/en/Algernon-Pharmaceuticals-to-File-End-of-Phase-2-Meeting-Request-with-U-S-FDA-for-Possible-Ifenprodil-Phase-3-COVID-19-Trial.html
https://www.pharmaceutical-technology.com/news/algernon-lung-scarring-endpoint/
https://www.globenewswire.com/news-release/2020/12/30/2151699/0/en/Algernon-Pharmaceuticals-Provides-Year-End-Summary-of-Key-Activities.html
https://www.globenewswire.com/news-release/2020/12/24/2150551/0/en/Algernon-Pharmaceuticals-Announces-Last-Patient-Out-in-Multinational-Phase-2b-3-Human-Study-of-Ifenprodil-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/12/24/2150551/0/en/Algernon-Pharmaceuticals-Announces-Last-Patient-Out-in-Multinational-Phase-2b-3-Human-Study-of-Ifenprodil-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/12/15/2145345/0/en/Algernon-Pharmaceuticals-Announces-Positive-Trending-Interim-Data-for-its-Phase-2b-3-Ifenprodil-COVID-Study.html
https://www.proactiveinvestors.com/companies/news/932817/algernon-wins-data-and-safety-monitoring-board-approval-to-continue-its-phase-2b3-human-study-of-ifenprodil-to-treat-covid-19-932817.html
https://www.globenewswire.com/news-release/2020/09/29/2100515/0/en/Algernon-Announces-Enrollment-of-100-Patients-in-Multinational-2b-3-Human-Study-of-Ifenprodil-for-Treatment-of-COVID-19.html
https://www.globenewswire.com/news-release/2020/09/02/2087723/0/en/Algernon-Announces-Enrollment-of-50th-Patient-in-Multinational-2b-3-Human-Study-of-Ifenprodil-for-Treatment-of-COVID-19.html
https://www.globenewswire.com/news-release/2020/08/13/2077876/0/en/Algernon-Announces-Enrollment-of-First-U-S-Patient-in-Multinational-Phase-2b-3-Human-Study-of-Ifenprodil-for-Treatment-of-COVID-19.html
https://www.globenewswire.com/news-release/2020/08/05/2073542/0/en/Algernon-Announces-Enrollment-of-First-Patient-in-2b-3-Human-Study-of-Ifenprodil-for-Treatment-of-COVID-19.html
https://www.globenewswire.com/news-release/2020/07/16/2063293/0/en/Algernon-Announces-First-U-S-Clinical-Trial-Site-in-Florida-for-Phase-2b-3-Human-Study-of-Ifenprodil-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/07/07/2058544/0/en/Algernon-Begins-Screening-Patients-for-Phase-2-Ifenprodil-IPF-and-Chronic-Cough-Human-Study-in-Australia.html
https://www.clinicaltrialsarena.com/news/algernon-us-ethics-approval/
https://www.globenewswire.com/news-release/2020/06/04/2043925/0/en/Algernon-Receives-U-S-FDA-Clearance-for-Multinational-Phase-2b-3-Human-Study-to-Evaluate-Ifenprodil-as-a-Potential-Therapeutic-for-COVID-19.html
https://www.clinicaltrialsarena.com/news/algernon-seeks-ethics-approval-australia/
https://www.globenewswire.com/news-release/2020/05/06/2028431/0/en/Algernon-Receives-First-Ethics-Approval-for-Phase-2-Ifenprodil-IPF-and-Chronic-Cough-Human-Study-in-Australia.html
https://www.biospectrumasia.com/news/25/15885/algernon-re-purposes-ifenprodil-drug-against-covid-19.html
https://www.globenewswire.com/news-release/2020/04/29/2024542/0/en/Algernon-Receives-Clearance-from-Health-Canada-for-Ifenprodil-COVID-19-Phase-2b-3-Multinational-Clinical-Trial.html
https://www.globenewswire.com/news-release/2020/04/15/2016426/0/en/Algernon-Receives-Positive-Feedback-from-U-S-FDA-for-New-Ifenprodil-Intravenous-Formulation.html
https://www.globenewswire.com/news-release/2020/04/13/2015035/0/en/Algernon-Receives-Positive-Feedback-from-U-S-FDA-for-Ifenprodil-COVID-19-Human-Trial-Appoints-U-S-Ambassador-Rtd-Howard-Gutman-to-Advisory-Board.html
https://finance.yahoo.com/news/algernon-appoints-u-company-cgmp-123010375.html
https://www.globenewswire.com/news-release/2020/03/20/2004243/0/en/Algernon-Appoints-Novotech-as-CRO-For-Phase-2-Coronavirus-Ifenprodil-Trial.html
Market Place
Share 
